NCT04814407View on ClinicalTrials.gov

Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer

RecruitingOBSERVATIONAL
Enrollment

900

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Lung Cancer
Interventions
DIAGNOSTIC_TEST

Blood-derived DNA methylation detection

Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.

Trial Locations (1)

100225

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER